292 related articles for article (PubMed ID: 30626493)
1. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma.
Hong YK; Li Y; Pandit H; Li S; Pulliam Z; Zheng Q; Yu Y; Martin RCG
Cell Immunol; 2019 Feb; 336():66-74. PubMed ID: 30626493
[TBL] [Abstract][Full Text] [Related]
2. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma.
Li Y; Hong YK; Wang X; Pandit H; Zheng Q; Yu Y; Shi X; Chen Y; Tan M; Pulliam Z; Bhutiani N; Lin A; Badach J; Zhang P; Martin RC
Clin Transl Immunology; 2022; 11(12):e1430. PubMed ID: 36452477
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
8. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
9. Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma.
Qiang N; Ao J; Nakamura M; Chiba T; Kusakabe Y; Kaneko T; Kurosugi A; Kogure T; Ma Y; Zhang J; Ogawa K; Kan M; Iwanaga T; Sakuma T; Kanayama K; Kanzaki H; Kojima R; Nakagawa R; Kondo T; Nakamoto S; Muroyama R; Kato J; Mimura N; Ma A; Jin J; Kato N
Int Immunopharmacol; 2023 May; 118():110068. PubMed ID: 37001386
[TBL] [Abstract][Full Text] [Related]
10. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
11. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
12. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
13. Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma.
Wang Q; Luan W; Warren L; Kadri H; Kim KW; Goz V; Blank S; Isabel Fiel M; Hiotis SP
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):574-582. PubMed ID: 26786094
[TBL] [Abstract][Full Text] [Related]
14. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
15. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes.
Hirano S; Iwashita Y; Sasaki A; Kai S; Ohta M; Kitano S
J Gastroenterol Hepatol; 2007 May; 22(5):690-6. PubMed ID: 17444857
[TBL] [Abstract][Full Text] [Related]
16. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
17. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
19. Triune Nanomodulator Enables Exhausted Cytotoxic T Lymphocyte Rejuvenation for Cancer Epigenetic Immunotherapy.
Li J; Zhao Q; Zhang N; Wu L; Wang Q; Li J; Pan Q; Pu Y; Luo K; Gu Z; He B
ACS Nano; 2024 May; 18(20):13226-13240. PubMed ID: 38712706
[TBL] [Abstract][Full Text] [Related]
20. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
